Farhanah Aziz, Muneera Smith and Jonathan M Blackburn.
http//dx.doi.org/10.5772/intechopen.75200
Read the Review and Learn
Sengenics can help, with solutions to support discovery of biomarker signatures. Our high-density protein microarray assays enable highly specific and reproducible detection of disease-relevant autoantibodies directly from patient serum.
The Immune System has Something to Say.
Are You Listening?
Tools for early disease detection are lacking, so how do we detect disease before symptoms are present? The Immune System responds quickly and specifically to aberrant proteins produced throughout the disease process, marking a disease, often long before symptoms occur. The Sengenics i-Ome platform can screen 1600+ autoantibodies from a single serum sample enabling you to identify early markers of disease, predict outcomes and identify potential new drug targets.
"*" indicates required fields
